Impact of margin distance on recurrence and survival following breast-conserving surgery after neoadjuvant systemic therapy.

IF 7.6 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-05-19 DOI:10.1038/s41523-025-00756-5

C Florin Pop, Clémence Ortega, Mathilde Lecomte, Paulus Kristanto, Chirine Khaled, Filip De Neubourg, Antoine Desmet, Evandro De Azambuja, Denis Larsimont, Isabelle Veys

{"title":"Impact of margin distance on recurrence and survival following breast-conserving surgery after neoadjuvant systemic therapy.","authors":"C Florin Pop, Clémence Ortega, Mathilde Lecomte, Paulus Kristanto, Chirine Khaled, Filip De Neubourg, Antoine Desmet, Evandro De Azambuja, Denis Larsimont, Isabelle Veys","doi":"10.1038/s41523-025-00756-5","DOIUrl":null,"url":null,"abstract":"<p><p>Current evidence does not support the application of \"no-ink-on-tumor\" negative margins following breast-conserving surgery (BCS) in breast cancer (BC) patients who have received neoadjuvant systemic treatment (NST). We compared loco-regional free survival (LRFS), disease-free survival (DFS), and overall survival (OS) based on different tumor margin distance thresholds in a cohort of 235 BC patients treated with NST and subsequent BCS between 01/2015 and 12/2019. The 5-year LRFS was 81.6% in patients with \"no-ink-on-tumour\", margins and 71.0% in those with positive margins (p = 0.584). Margins >1 mm were associated with superior outcomes, with a 5-year LRFS of 84.0% compared to 69.3% in patients with margins ≤1 mm (p = 0.005). Additionally, margins >1 mm were significantly correlated with longer DFS (p = 0.028) and OS (p = 0.001). These findings suggest that a surgical margin distance >1 mm provides the best LRFS, DFS, and OS outcomes for this group of BC patients.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"45"},"PeriodicalIF":7.6000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089308/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00756-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Current evidence does not support the application of "no-ink-on-tumor" negative margins following breast-conserving surgery (BCS) in breast cancer (BC) patients who have received neoadjuvant systemic treatment (NST). We compared loco-regional free survival (LRFS), disease-free survival (DFS), and overall survival (OS) based on different tumor margin distance thresholds in a cohort of 235 BC patients treated with NST and subsequent BCS between 01/2015 and 12/2019. The 5-year LRFS was 81.6% in patients with "no-ink-on-tumour", margins and 71.0% in those with positive margins (p = 0.584). Margins >1 mm were associated with superior outcomes, with a 5-year LRFS of 84.0% compared to 69.3% in patients with margins ≤1 mm (p = 0.005). Additionally, margins >1 mm were significantly correlated with longer DFS (p = 0.028) and OS (p = 0.001). These findings suggest that a surgical margin distance >1 mm provides the best LRFS, DFS, and OS outcomes for this group of BC patients.

Abstract Image

查看原文本刊更多论文

切缘距离对保乳术后新辅助全身治疗后复发及生存的影响。

目前的证据不支持在接受新辅助全身治疗（NST）的乳腺癌（BC）患者保乳手术（BCS）后“肿瘤上无墨”阴性切缘的应用。我们比较了2015年1月至2019年12月期间，235名接受NST治疗和随后的BCS治疗的BC患者基于不同肿瘤边缘距离阈值的局部-区域无生存（LRFS）、无病生存（DFS）和总生存（OS）。边缘无墨瘤患者的5年LRFS为81.6%，边缘阳性患者的5年LRFS为71.0% （p = 0.584）。切缘≤1 mm患者的5年LRFS为84.0%，而切缘≤1 mm患者的5年LRFS为69.3% （p = 0.005）。此外，切缘>.1 mm与较长的DFS （p = 0.028）和OS （p = 0.001）显著相关。这些结果表明，对于这组BC患者，手术切缘距离bb0.1 mm可提供最佳的LRFS、DFS和OS结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.